Business Context and Reporting Period
This Form 8-K is a current report filed by ReShape Lifesciences Inc. (not Vyome Holdings, Inc.) on November 8, 2023. The filing serves to announce the company's financial results for the three and nine months ended September 30, 2023. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1), which is not included in the input content.
Material Changes
No specific material changes versus prior periods are detailed in this document. The filing solely indicates that results for the period ended September 30, 2023, have been issued.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It explicitly states that the information furnished is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (Press Release dated November 8, 2023), as they are absent from this summary text.
- Confirm the company name is ReShape Lifesciences Inc. (Ticker: RSLS), noting the discrepancy with the "Vyome Holdings, Inc." label in the request metadata.
- Review the full press release for any updated guidance or operational milestones not captured in this 8-K cover page.